Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biomarker discovery in neurodegenerative diseases: a proteomic approach.

Literature DB >> 18938247

Biomarker discovery in neurodegenerative diseases: a proteomic approach.

Abstract

Biomarkers for neurodegenerative disorders are essential to facilitate disease diagnosis, ideally at early stages, monitor disease progression, and assess response to existing and future treatments. Application of proteomics to the human brain, cerebrospinal fluid and plasma has greatly hastened the unbiased and high-throughput searches for novel biomarkers. There are many steps critical to biomarker discovery, whether for neurodegenerative or other diseases, including sample preparation, protein/peptide separation and identification, as well as independent confirmation and validation. In this review we have summarized current proteomics technologies involved in discovery of biomarkers for neurodegenerative diseases, practical considerations and limitations of several major aspects, as well as the current status of candidate biomarkers revealed by proteomics for Alzheimer and Parkinson diseases.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Biomarkers

Year: 2008 PMID： 18938247 PMCID： PMC2939006 DOI： 10.1016/j.nbd.2008.09.004

Source DB: PubMed Journal: Neurobiol Dis ISSN： 0969-9961 Impact factor: 5.996

90 in total

1. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

Authors: Takahiko Tokuda; Sultan A Salem; David Allsop; Toshiki Mizuno; Masanori Nakagawa; Mohamed M Qureshi; Joseph J Locascio; Michael G Schlossmacher; Omar M A El-Agnaf
Journal: Biochem Biophys Res Commun Date: 2006-08-14 Impact factor: 3.575

2. Identification of proteins in human substantia nigra.

Authors: Efstathia Kitsou; Sheng Pan; Jianpeng Zhang; Min Shi; Aram Zabeti; Dennis W Dickson; Roger Albin; Marla Gearing; Daniel T Kashima; Yan Wang; Richard P Beyer; Yong Zhou; Catherine Pan; W Michael Caudle; Jing Zhang
Journal: Proteomics Clin Appl Date: 2008-05 Impact factor: 3.494

3. Direct analysis of protein complexes using mass spectrometry.

Authors: A J Link; J Eng; D M Schieltz; E Carmack; G J Mize; D R Morris; B M Garvik; J R Yates
Journal: Nat Biotechnol Date: 1999-07 Impact factor: 54.908

4. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Authors: Annika Olsson; Hugo Vanderstichele; Niels Andreasen; Geert De Meyer; Anders Wallin; Björn Holmberg; Lars Rosengren; Eugeen Vanmechelen; Kaj Blennow
Journal: Clin Chem Date: 2004-11-24 Impact factor: 8.327

Review 5. Alzheimer's disease: clinical features, pathogenesis, and treatment.

Authors: K L Rathmann; C S Conner
Journal: Drug Intell Clin Pharm Date: 1984-09

6. Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometry.

Authors: Giuseppina Maccarrone; Dale Milfay; Isabel Birg; Marcus Rosenhagen; Florian Holsboer; Rudolf Grimm; Jerome Bailey; Nina Zolotarjova; Christoph W Turck
Journal: Electrophoresis Date: 2004-07 Impact factor: 3.535

Review 7. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs.

Authors: Mark S Forman; John Q Trojanowski; Virginia M-Y Lee
Journal: Nat Med Date: 2004-10 Impact factor: 53.440

Review 8. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications.

Authors: Daniel M Skovronsky; Virginia M-Y Lee; John Q Trojanowski
Journal: Annu Rev Pathol Date: 2006 Impact factor: 23.472

Review 9. Glycoprotein enrichment through lectin affinity techniques.

Authors: Yehia Mechref; Milan Madera; Milos V Novotny
Journal: Methods Mol Biol Date: 2008

10. Serum biomarkers for Alzheimer's disease: proteomic discovery.

Authors: Dwight C German; Prem Gurnani; Animesh Nandi; Harold R Garner; Wayne Fisher; Ramon Diaz-Arrastia; Padraig O'Suilleabhain; Kevin P Rosenblatt
Journal: Biomed Pharmacother Date: 2007-06-18 Impact factor: 6.529

30 in total

Review 1. Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors: Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal: Mol Neurobiol Date: 2012-06-27 Impact factor: 5.590

Review 2. Biomarkers for cognitive impairment in Parkinson disease.

Authors: Min Shi; Bertrand R Huber; Jing Zhang
Journal: Brain Pathol Date: 2010-05 Impact factor: 6.508

3. An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach.

Authors: Giovanna Cenini; Ada Fiorini; Rukhsana Sultana; Marzia Perluigi; Jian Cai; Jon B Klein; Elizabeth Head; D Allan Butterfield
Journal: Free Radic Biol Med Date: 2014-08-20 Impact factor: 7.376

Biomarker discovery in neurodegenerative diseases: a proteomic approach.

1. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

2. Identification of proteins in human substantia nigra.

3. Direct analysis of protein complexes using mass spectrometry.

4. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Review 5. Alzheimer's disease: clinical features, pathogenesis, and treatment.

6. Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometry.

Review 7. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs.

Review 8. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications.

Review 9. Glycoprotein enrichment through lectin affinity techniques.

10. Serum biomarkers for Alzheimer's disease: proteomic discovery.

Review 1. Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Review 2. Biomarkers for cognitive impairment in Parkinson disease.

3. An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach.

4. Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Review 5. Proteomics in Human Parkinson's Disease: Present Scenario and Future Directions.

6. Genomic and proteomic responses to environmentally relevant exposures to dieldrin: indicators of neurodegeneration?

Review 7. Proteomics of gliomas: initial biomarker discovery and evolution of technology.

Review 8. Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.

9. Biological markers and Alzheimer disease: a canadian perspective.

10. Plasma proteomics for the identification of Alzheimer disease.